Skip Navigation

JNCI Journal of the National Cancer Institute 2007 99(8):590-591; doi:10.1093/jnci/djk174
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Benowitz, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Benowitz, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2007.

NEWS

Liver Cancer Biomarkers Struggling to Succeed

Steve Benowitz

The first 10% of the full text of this article appears below.

Liver cancer is an international problem, as the third most common cancer and the fifth leading cause of cancer death worldwide. In the United States, the rising number of cases of the hepatitis C virus (HCV) has helped liver cancer take center stage. It currently is the fastest-growing cancer in incidence in the United States, and it is expected to continue climbing over the next 20 years.

But by the time liver cancer is diagnosed, sometimes after years of chronic hepatitis infection and cirrhosis, treatment options are often limited. Surgical removal is a possibility, if the tumor is small enough, but for some, a liver transplant is the only viable hope. Fewer than 5% of those diagnosed with liver cancer survive for 5 years.

Jorge Marrero, M.D., medical oncologist Paul Brenner, M.D., and their . . . [Full Text of this Article]

Biomarkers Abound

Triaging Biomarkers


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?